Tags

Type your tag names separated by a space and hit enter

Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment.
Case Rep Med. 2020; 2020:6865190.CR

Abstract

A 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for insulin quickly declined, and she took her last dose of insulin 19 days after the first dose of fenofibrate, having regained endogenous control of blood glucose concentrations. She has now been insulin independent for one year and 9 months. Unstimulated C-peptide has increased by 51% (317 to 479 pmol/l), and IA-2 autoantibody level has decreased by 65% (49 to 17 × 103 arbitrary units). Fenofibrate is a widely used drug for reducing triglyceride and cholesterol levels. Fenofibrate reverses and prevents autoimmune diabetes in nonobese diabetic (NOD) mice by increasing the amount of the sphingolipid sulfatide in islets. Sphingolipid metabolism is otherwise abnormal in the islets at diagnosis of type 1 diabetes. In conclusion, we describe a 19-year-old patient with classical newly diagnosed type 1 diabetes, which following fenofibrate treatment has been without insulin for 21 months.

Authors+Show Affiliations

The Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.The Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

32508930

Citation

Buschard, Karsten, et al. "Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient Following Fenofibrate Treatment." Case Reports in Medicine, vol. 2020, 2020, p. 6865190.
Buschard K, Holm LJ, Feldt-Rasmussen U. Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment. Case Rep Med. 2020;2020:6865190.
Buschard, K., Holm, L. J., & Feldt-Rasmussen, U. (2020). Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment. Case Reports in Medicine, 2020, 6865190. https://doi.org/10.1155/2020/6865190
Buschard K, Holm LJ, Feldt-Rasmussen U. Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient Following Fenofibrate Treatment. Case Rep Med. 2020;2020:6865190. PubMed PMID: 32508930.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment. AU - Buschard,Karsten, AU - Holm,Laurits J, AU - Feldt-Rasmussen,Ulla, Y1 - 2020/05/14/ PY - 2019/08/29/received PY - 2020/04/29/accepted PY - 2020/6/9/entrez PY - 2020/6/9/pubmed PY - 2020/6/9/medline SP - 6865190 EP - 6865190 JF - Case reports in medicine JO - Case Rep Med VL - 2020 N2 - A 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for insulin quickly declined, and she took her last dose of insulin 19 days after the first dose of fenofibrate, having regained endogenous control of blood glucose concentrations. She has now been insulin independent for one year and 9 months. Unstimulated C-peptide has increased by 51% (317 to 479 pmol/l), and IA-2 autoantibody level has decreased by 65% (49 to 17 × 103 arbitrary units). Fenofibrate is a widely used drug for reducing triglyceride and cholesterol levels. Fenofibrate reverses and prevents autoimmune diabetes in nonobese diabetic (NOD) mice by increasing the amount of the sphingolipid sulfatide in islets. Sphingolipid metabolism is otherwise abnormal in the islets at diagnosis of type 1 diabetes. In conclusion, we describe a 19-year-old patient with classical newly diagnosed type 1 diabetes, which following fenofibrate treatment has been without insulin for 21 months. SN - 1687-9627 UR - https://www.unboundmedicine.com/medline/citation/32508930/Insulin_Independence_in_Newly_Diagnosed_Type_1_Diabetes_Patient_following_Fenofibrate_Treatment L2 - https://doi.org/10.1155/2020/6865190 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.